Perrigo Company plc (PRGO) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-27..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-27..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-27..
Borrowing debt
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 11.40M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 3.28B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 7.61B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | (m) | (m) | $11.40M | $3.28B | (m) | (m) | $7.61B | (m) |
| 2026-03-28 | (m) | (m) | $11.40M | $3.62B | (m) | (m) | $7.98B | (m) |
| 2025-12-31 | (m) | (m) | $36.60M | $3.60B | (m) | (m) | $8.54B | (m) |
| 2025-09-27 | (m) | (m) | $36.60M | $3.61B | (m) | (m) | $10.08B | (m) |
| 2025-06-28 | (m) | (m) | $36.40M | $3.62B | (m) | (m) | $10.09B | (m) |
| 2025-03-29 | (m) | (m) | $36.20M | $3.59B | (m) | (m) | $9.76B | (m) |
| 2024-12-31 | (m) | (m) | $36.40M | $3.58B | (m) | (m) | $9.65B | (m) |
| 2024-09-28 | (m) | (m) | $440.70M | $4.31B | (m) | (m) | $11.20B | (m) |
| 2024-06-29 | (m) | (m) | $440.80M | $3.62B | (m) | (m) | $10.40B | (m) |
| 2024-03-30 | (m) | (m) | $440.60M | $3.62B | (m) | (m) | $10.64B | (m) |
| 2023-12-31 | (m) | (m) | $440.60M | $3.63B | (m) | (m) | $10.81B | (m) |
| 2023-09-30 | (m) | (m) | $38.10M | $4.05B | (m) | (m) | $10.76B | (m) |
| 2023-07-01 | (m) | (m) | $38.40M | $4.06B | (m) | (m) | $10.96B | (m) |
| 2023-04-01 | (m) | (m) | $38.80M | $4.06B | (m) | (m) | $10.95B | (m) |
| 2022-12-31 | (m) | (m) | $36.20M | $4.07B | (m) | (m) | $11.02B | (m) |
| 2022-10-01 | (m) | (m) | $33.50M | $4.08B | (m) | (m) | $10.68B | (m) |
| 2022-07-02 | (m) | (m) | $30.80M | $4.09B | (m) | (m) | $10.92B | (m) |
| 2022-04-02 | (m) | (m) | $4.60M | $3.51B | (m) | (m) | $10.39B | (m) |
| 2021-12-31 | (m) | (m) | $603.80M | $2.92B | (m) | (m) | $10.43B | (m) |
| 2021-10-02 | (m) | (m) | $629.40M | $2.92B | (m) | (m) | $10.92B | (m) |
| 2021-07-03 | (m) | (m) | $630.10M | $2.93B | (m) | (m) | $11.23B | (m) |
| 2021-04-03 | (m) | (m) | $35.80M | $3.53B | (m) | (m) | $11.32B | (m) |
| 2020-12-31 | (m) | (m) | $37.80M | $3.53B | (m) | (m) | $11.49B | (m) |
| 2020-09-26 | (m) | (m) | $16.50M | $3.54B | (m) | (m) | $11.58B | (m) |
| 2020-06-27 | (m) | (m) | $606.50M | $3.54B | (m) | (m) | $12.13B | (m) |
| 2020-03-28 | (m) | (m) | $287.80M | $3.18B | (m) | (m) | $11.40B | (m) |
| 2019-12-31 | (m) | (m) | $3.40M | $3.37B | (m) | (m) | $11.30B | (m) |
| 2019-09-28 | (m) | (m) | $3.10M | $3.36B | (m) | (m) | $11.31B | (m) |
| 2019-06-29 | (m) | (m) | $398.80M | $3.08B | (m) | (m) | $11.43B | (m) |
| 2019-03-30 | (m) | (m) | $467.90M | $2.75B | (m) | (m) | $11.12B | (m) |
| 2018-12-31 | (m) | (m) | $190.20M | $3.05B | (m) | (m) | $10.98B | (m) |
| 2018-09-29 | (m) | (m) | $194.20M | $3.07B | (m) | (m) | $10.94B | (m) |
| 2018-06-30 | (m) | (m) | $197.70M | $3.09B | (m) | (m) | $11.23B | (m) |
| 2018-03-31 | (m) | (m) | $58.00M | $3.28B | (m) | (m) | $11.64B | (m) |
| 2017-12-31 | (m) | (m) | $70.40M | $3.27B | (m) | (m) | $11.63B | (m) |
| 2017-09-30 | (m) | (m) | $417.10M | $3.28B | (m) | (m) | $11.84B | (m) |
| 2017-07-01 | (m) | (m) | $406.90M | $3.27B | (m) | (m) | $11.79B | (m) |
| 2017-04-01 | (m) | (m) | $1.18B | $4.62B | (m) | (m) | $13.98B | (m) |
| 2016-12-31 | (m) | (m) | $572.80M | $5.22B | (m) | (m) | $13.87B | (m) |
| 2016-10-01 | (m) | (m) | $265.00M | $5.64B | (m) | (m) | $17.47B | (m) |
| 2016-07-02 | (m) | (m) | $758.10M | $5.65B | (m) | (m) | $19.53B | (m) |
| 2016-04-02 | (m) | (m) | $619.20M | $5.90B | (m) | (m) | $19.73B | (m) |
| 2015-12-31 | (m) | (m) | $1.02B | $4.97B | (m) | (m) | $19.39B | (m) |
| 2015-09-26 | (m) | (m) | $58.20M | $5.23B | (m) | $523.00M | $19.70B | (m) |
| 2015-06-27 | (m) | (m) | $58.20M | $5.25B | (m) | $798.30M | $19.72B | (m) |
| 2015-03-28 | (m) | (m) | $355.60M | $4.37B | (m) | $3.45B | $16.18B | (m) |
| 2014-12-27 | (m) | (m) | $362.30M | $4.44B | (m) | $3.62B | $16.46B | (m) |
| 2014-09-27 | (m) | (m) | $141.50M | $3.05B | (m) | $913.10M | $13.78B | (m) |
| 2014-06-28 | (m) | (m) | $141.60M | $3.09B | (m) | $805.40M | $13.88B | (m) |
| 2014-03-29 | (m) | (m) | $141.70M | $3.13B | (m) | $617.10M | $13.74B | (m) |
| 2013-12-28 | (m) | (m) | $141.20M | $3.16B | (m) | $606.60M | $13.71B | (m) |
| 2013-06-29 | (m) | (m) | $41.20M | $1.93B | (m) | $779.90M | $5.35B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |